In gefitinib-sensitive lung cancer cells with EGFR mutations and amplifications, continued activation of PI3K signaling by the PIK3CA oncogenic mutant was sufficient to abrogate gefitinib-induced apoptosis [35]. The gene discussed is EGFR; the disease is lung cancer.